NSECertificate under SEBI (Depositories and Participants) Regulations, 20188 Jul 2026 · 8 Jul 2026, 04:05 pm

Certificate under SEBI (Depositories and Participants) Regulations, 2018

GlaxoSmithKline Pharmaceuticals Limited · GLAXO

✦ AI Summary

GlaxoSmithKline Pharmaceuticals Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and listing of new securities on stock exchanges.

Analysis Scores

Earnings Impact1/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact1/10
Market Sentiment1/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018

Attachments (1)

📄

GLAXO1924_08072026160548_clause_74.pdf

pdf

Download →
View document text
GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 8th July 2026 BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sir, Sub: Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June 2026 In Compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find enclosed herewith a copy of the Certificate received from Kfin Technologies Limited, the Registrar and share Transfer Agent of the Company, for the quarter ended 30th June 2026. Kindly take the above intimation on your records. Thanking you Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President – Administration, Real Estate & Company Secretary Encl: CIN: L24239MH1924PLC001151 KFIN/CERT/74(5)/JUN/2026 Date: 07/07/2026 The Company Secretary GlaxoSmithKline Pharmaceuticals Limited Dr. Annie Besant Road Worli, Mumbai-400030. Dear Sir(s), Sub: Certificate under Regulation 74(5) for the quarter ended June 30, 2026. Pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, we hereby confirm that the securities received from the depository participants for dematerialisation during the quarter ended June 30, 2026, were confirmed (accepted / rejected) to the depositories by us and the securities comprised in the said certificates have been listed on stock exchanges where the earlier issued securities are listed. We also hereby confirm that the security certificates received for dematerialisation have been mutilated and cancelled after due verification by the depository participant and the name of the depositories have been substituted in register of members as the registered owner within 30 days. Request to kindly take the above on record. Thanking you, Yours faithfully, For KFin Technologies Limited Dnyanesh Gharote Vice President